107.  Mitra R., Srinivasan A., Mesaros C., Thomas D., Mohiuddin A., Li L., Badve S., Edenberg H., Blair I., and Potter D. A. CYP3A5 gene expression is a candidate biomarker for early recurrence of non-small cell lung cancer. Clinical Cancer Research 2009 (revised).

106.  Wang G., Wang, Yadong Wang, Changy Shen, Yi-wen Huang, Kun Huang, Tim Huang, Kenneth Nephew, Lang Li, and Yunlong Liu, RNA Polymerase II binding patterns reveal genomic regions involved in microRNA gene regulation, Plos One 2011 (in press).

105.  Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L., Kulesavage C, Snyder AJ, Nephew KP, Matei DE.A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 2011 (in press).

104.  Friedman AN, Yu Z, Juliar BE, Nguyen JT, Strother M, Quinney SK, Li L, Inman M, Gomez G, Shihabi Z, Moe S. Independent influence of dietary protein on markers of kidney function and disease in obesity. Kidney Int. 2011 (in press).

103.  Hayes DF, Skaar TC, Rae JM, Henry NL, Nguyen AT, Stearns V, Li L, Philips S, Desta Z, and Flockhart DA. Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. The Journal of Clinical Pharmacology and Therapeutics 2011 (in press).

102.  Wang X., Hickey R., Malkas L., Koch M., Li L., Zhang S., Sandusky GE, Grignon DJ, Eble JN, Cheng L. Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. The Prostate 2011 (in press).

101.  Zhou F., Zhao Q., Edenberg H. J., Goodlett C. R., Liu Y., Li L. Microarray and gene set enrichment analysis of differential gene expression upon alcohol exposure at early neurulation. BMC Genomics 2011 (in press).

100.  Li L., Borges-Gonzales S, Robarge J., Sheng C., Desta Z., and Flockhart D. A Penalized mixture model approach in genotype/phenotype association analysis for quantitative phenotype. Cancer Informatics, 2010, 9, 93-103.

99.  Hahn N., Kelley M., Klaunig J. E., Koch M. O., Li L., and Sweeney, C.J. Prostate Cancer Germline Pharmacogenetics - Diagnostic, Prevention, and Therapeutic Application. Future Medicine, 2009 (in press).

98.  Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes DF, Storniolo AM, Clauw DJ. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treatment, 2009, (in press)

97.  Schneider B., Radovivh M., Flockhart DA., Carpenter JS., Li L., Robarge JD., Storniolo AM,Hancock BA, Skaar TC, Sledge GW. Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes. Breast Cancer Research and Treatment, 2009, 116, 543-549.

96.  Li M., Paik H., Balch C., Kim Y., Li L., Huang H-M. T., Nephew P. K., Kim, S. Enriched transcription factor binding sites in hypermethylated gene promoters in cancer cells. Bioinformatics 2009, (in press).

95.  Zhou F., Zhao Q., Edenberg H. J., Goodlett C. R., Liu Y., Li L. Microarray and gene set enrichment analysis of differential gene expression upon alcohol exposure at early neurulation. ACER 2009 (in press).

94.  Kim S., Hall S.D., and Li L. Optimal MCMC algorithm in the nonlinear mixed models. Journal of Biopharmaceutical Statistics. 2009 (in press).

93.  Yu M., Ni L., Walsh J.P., Robarge J.D., Desta Z., and Li L. Two-stage designs for predictive marker validation in randomized clinical trials. Biometrics, 2009, (in press).

92.  Desta Z., Li L., Flockhart D. A. A breath test for CYP2C19. Journal of Pharmacologic Experimental Therapeutics, 2009 (in press).

91.  Wang Z., Luis R., Quinney S., Kim S., and Li L. Pharmacokinetics parameter data mining – A case study. Journal of Medical Informatics, 2009 (in press).

90.  Shen C., Liu Y., Nephew K., Huang T., and Li L. Estrogen regulatory pathway and the impact of selective estrogen receptor modulator. Nature Genetics, 2009 (submitted).

89.  Quinney S.K., Feng W. Miao J., Hall S.D., and Li L. In-vitro/in-vivo Prediction of Midazolam Clearance and Its Variability – A Meta-Analysis Approach. Journal of Pharmacokinetics and Pharmacodynamics, 2009, (submitted).

88.  Quinney S.K., Feng W. Miao J., Hall S.D., and Li L. How much confidence do we have on DDI prediction? – A peek from in-vitro ki prediction. Clinical Pharmacology and Therapeutics, 2009, (submitted).

87.  Quinney S.K., Zhang X., Lucksiri A., Gorski J.C., Li L., and Hall S.D. A Physiologically-Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin. Clinical Pharmacokinetics, 2009 (submitted).

86.  Kim S., Quinney S.K., Wang Z., Hall S.D., and Li L. A Population Physiologically-Based Pharmacokinetic Model of Competitive Inhibition of CYP3A by Ketoconazole. Clinical Pharmacology and Therapeutics, 2009 (submitted).

85.  Kim S., Wang Z. and Li L. The application of particle-swamping algorithm in nonlinear mixed model. System Biology 2009 (submitted).

84.  Kim S. and Li L. The optimal MCMC when the model is non-identifiable. Biometrics 2009 (submitted).

83.  Azzouz F. and Li L. An integrated PG/PK/PD model. Biometric 2009 (submitted).

82.  Balch K., Nephew K., and Li L. Which theory is true, Heritable methylation or random methylation? Nucleotide Acid Research, 2009 (sumitted).

81.  Jeong J., Li L., Liu Y., Nephew K.P., Huang T., Shen C. An Empirical Bayes Model for Gene Expression and Methy- lation Pro files in Antiestrogen Resistant Breast Cancer. BMC Biomedical Genetics, 2010, 3: 55.

80.  Borges S., Desta Z., Jin Y., Faouzi A., Robarge JD., Philip S., Nguyen A, Stearns V., Hayes D., Rae JM, Skaar TC, Flockhart DA, Li L.. A Composite Functional Genetic and Co-Medication CYP2D6 Activity Score In Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients. Journal of Clinical Pharmacology, 2010, 450-458. NIHMS 220544.

79.  Wang Z. Kim S., and Li L., Non-compartment model/compartment model transformation. BMC System Biology, 2010, 4, 1:S8. NIHMS 254537.

78.  Henry NL, Nguyen A, Azzouz F, Li L, Robarge J, Philips S, Cao D, Skaar TC, Rae JM, Storniolo AM, Flockhart DA, Hayes DF, Stearns V. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. British Journal of Cancer. 2010, 102, 294-300. (PMC2816645)

77.  Henry NL, Pchejetski D, A’Hern R, Nguyen A, Charles P, Waxman J, Li L, Storniolo A, Hayes DF, Flockhart DA, Stearns V, and Stebbing J. A Distinct Inflammatory Signature in Patients with Aromatase Inhibitor-Associated Musculoskeletal Syndrome. British Journal of Cancer. 2010, 103, 291-296. (PMC2920022).

76.  Friedman AN, Strother M, Quinney SK, Hall SD, Perkins SM, Brizendine EJ, Inman M, Gomez G, Shihabi Z, Moe S, and Li L. Measure the glomerular filtration rate in obese individuals without overt kidney disease. Nephron Clinical Practice, 2010, 116, 224-234.

75.  Quinney S.K., Zhang X., Lucksiri A., Gorski J.C., Li L., and Hall S.D. A Physiologically-Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin. Drug Metab Dispos, 2010, 38, 241-8.

74.  Atkinson EJ., McDonnell SK, Witte TS., Crawford DC., Fan Y., Fridley B., Li D., Li L., Rodin A., Sadee W., Speed T., Weiss ST., Yang J., Yerges L., and Schaid D.J. Lessons learned from the Fifth Statistical Analysis Workshop of the Pharmacogenetics Research Network. The Pharmacogenetics Journal, 2010, 11, 297-303.

73.  Wang G., Yadong Wang, Mingxiang Teng, Denan Zhang, Lang Li, and Yunlong Liu, Signal Transducers and Activators of Transcription-1 (STAT1) Regulates microRNA Transcription in Interferon gamma-Stimulated HeLa Cells. Plos One, 2010 July 26; 5(7):e11794, PMID: 20668688

72.  Zane Z. T., Li L., Zhao Q., Badve S., Kesler K A. Differential Gene Expression Profiling of Esophageal Adenocarcinoma. The Journal of Thoracic and Cardiovascular Surgery. 2009, 137, 829-843.

71.  Schneider B., Radovivh M., Flockhart DA., Carpenter JS., Li L., Robarge JD., Storniolo AM,Hancock BA, Skaar TC, Sledge GW. Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes. Breast Cancer Research and Treatment, 2009, 116, 543-549.

70.  Zhou J., Qin Z., Quinney S. K., Kim S., Wang Z., Hall D. S., and Li L. Equivalence Tests between Model based Drug-Drug Interaction Simulations and and Published Drug-Drug Interaction. Journal of Biopharmaceutical Statistics. 2009, 19, 641-657.

69.  Zhou J., Qin Z., Quinney S. K., Kim S., Wang Z., Yu M., Chien J. Y., Lucksiri A., Hall D. S., and Li L. A new probabilistic rule for drug-drug interaction prediction. Journal of Pharmacokinetics and Pharmacodynamics. 2009, 36, 1-18. DOI: 10.1007/s10928-008-9107-3

68.  Srinivasan B.S., Chen J., Cheng C., Conti D., Duan S, Fridley BL, Gu X., Haines JL, Jorgenson E., Kraja A., Lasky-Su J., Li L, Wang D., Rodin A, Province M., and Ritchie M.D. Methods for analysis in pharmacogenomics: Lessons from the Pharmacogenetics Research Network (PGRN) Analysis Group. Pharmacogenomics Journal, 2009, 10, 243-251.

67.  Onitilo AA, McCarty CA, Wilke RA, Glurich I, Engel JM, Flockhart DA, Nguyen A, Li L, Mi D, Skaar TC, and Jin Y. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Research and Treatment. 2009, 115, 643-650.

66.  Miao J., Jin Y., Marunde R.L., Kim S., Quinney S., Radovich M., Li L., and Hall S.D. Association of Genotypes of the CYP3A Cluster with Midazolam Disposition In Vivo. Pharmacogenomics Journal, 2009, 9, 319-326. (Li L. is the corresponding author).

65.  Desta Z., Modak A., Nguyen PD, Lemler SM, Kurogi Y, Li L., Flockhart D. A. Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C] pantoprazole breast test. Journal of Pharmacologic Experimental Therapeutics, 2009, 329, 297-305.

64.  Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, Stearns V, Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. 2009, Pharmacogenomics, 9, 258-264.

63.  Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat. 2009 Oct;117(3):571-575.

62.  Wang Z, Kim S, Quinney SK, Guo Y, Hall SD, Rocha LM, Li L. Literature mining on pharmacokinetics numerical data: a feasibility study., J Biomed Inform. 2009, 42, 725-735. NIHMS107535.

61.  Haas DM, Hebert MF, Soldin OP, Flockhart DA, Madadi P, Nocon JJ, Chambers CD, Hankins, GD, Clark S, Wisner KL, Li L, Renbarger JL, Learman LA. Pharmacotherapy and pregnancy: highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy. Clinical Translational Science 2009;2:439-43.

60.  Ntukidem, NI, Nguyen AT, Stearns V., Rehman M., Schott A., Skaar T., Jin Y., Blanche P., Li L., Lemler S., Hayden J., Krauss RM, Desta Z., Flockhart D. A., Hayes D. Estrogen receptor genotypes, menopausal status and the lipid effects of tamoxifen. Journal of Clinical Pharamoclogy and Therapeutics, 2008, 85, 702-710.

59.  Wang, G., Wang, X., Li, L., Nephew, N.P., Edenberg, H.J., Zhou, F.C., Liu, Y. Identification of transcription factor and microRNA binding sites in responsible to fetal alcohol syndrome. BMC Genomics 1 Jan 2008 9 Suppl 1: p. S19. http://highwire.stanford.edu/cgi/medline/pmid;18366608

58.  Wang, X., Wang, G., Shen, C., Li, L., Edenberg, H.J., Sanford, J., Liu, Y. Using RNase sequence specificity to refine the identification of RNA-protein binding regions. BMC Genomics 1 Jan 2008 9 Suppl 1: p. S17. http://highwire.stanford.edu/cgi/medline/pmid;18366606

57.  55. Shen C., Wang Z., Shanker G., Zhang X., and Li L. A Hierarchical Statistical Model to Assess the Confidence of Peptides and Proteins Inferred from Tandem Mass Spectrometry. Bioinformatics, 2008. 24, 202-208.

56.  Feng W., Liu Y., Wu J., Nephew K.P., Huang T., Li L. A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology. BMC Genomics, 2008, 9, s23. http://www.biomedcentral.com/I47I-2164/9/S2-S23

55.  Jin Y., Hayes D F., Li L., Robarge D., Skaar T. C., Philips S., Nguyen A., Schott A., Hayden J., Lemler S., Storniolo A. M., Flockhart D. A., Stearns V. Menopausal Status and Estrogen Receptor Genotypes Influence Hot Flash Frequency and Composite Score Before and After Tamoxifen Therapy. Journal of Clinical Oncology, 2008, 26, 5849 - 5854.

54.  Li L., Yu M., Robarge J., Shen C., Jin Y., Borges-Gonzales S., Nguyen A., Skaar T., Desta Z., McLeod H., Sweeney C J., and Flockhart D. A penalized mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. Journal of Pharmaceutical Statistics 2008, 18, 1150-1177. PMID: 1899111, NIHMS 122359.

53.  Yu M., Kim S., Wang Z., Hall S, and Li L. Drug-drug interaction prediction: A Bayesian meta-analysis approach. Journal of Biopharmaceutical Statistics, 2008 18, 1063-1083.

52.  Li L., Yu M., Chin R., Lucksiri A., Flockhart D., and Hall S. Drug-drug interaction prediction: A Bayesian meta-analysis approach. Statistics in Medicine, 2007, 26, 3700 - 3721.

51.  Khalili A., Potter D., Yan P., Li L., Gray J., Huang T., Lin S. Gamma-Normal-Gamma Mixture Model for Detecting Differentially Methylated Loci in three cancer cell lines. Cancer Informatics, 2007, Journal Link.

50.  Li L, Hui S, Desta Z, Todd S, Nguyen A and Flockhart D. Estimating a positive false discovery rate for variable selection in pharmacogenetic studies. Journal of Pharmaceutical Statistics, 2007, 17, 883-902.

49.  Li L and Hui S. Positive false discovery rate estimate in Step-wise variable selection. Communication in Statistics – Simulation and Computation. 2007, 32, 2.

48.  Jones D. R., Ekins S., Li L., and Hall S. D. Computational approaches that predict metabolic intermediate complex formation with CYP3A4(+b¬¬5). Drug Metab. and Dispos. 2007, 35(9):1466-75

47.  Jin Y., Wang Y-H, Miao J., Li L., Kovacs R J., Marunde R., Hamman M A., Phillips S., Halligoss J., Hall S. D. Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy Subjects. Journal of Pharmacology and Experimental Therapeutics, 2007, 82, 579-585.

46.  Abbosh P. H., Li X., Li L., Gardner T. A., Kao C., and Nephew K. P. A conditionally replicative, WNT/beta-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. Cancer Gene Therapy, 2007, 1-10.

45.  Desta Z., Saussele T., Ward B., Blievernicht J., Li L., Klein K., Flockhart D A., Zanger M. U. Impact of CYP2B6 polymorphism on efavirenz metabolism in vitro. Pharmacogenomics. 2007, 8, 547-558.

44.  Robarge J. D., Li L., Desta Z., Nguyen A., and Flockhart D. A. Evaluating genetic nonmenclature of drug metabolizing enzyme. Journal of Clinical Pharmacology and Therapeutics, 2007, 82, 244-248.

43.  Li L. Discussion on parameter estimation for differential equations: a generalized smoothing approach. JRSS B. 2007, 69, 787-788.

42.  Humphrey T. L., Li L., Li X., Janowicz D. M., Fortney K. R., Zhao Q., Li W., McClintick J., Katz B. P., Wilks D. S., Edenberg H. J., Spinola S. M. Dysregulated immune profiles in skin and dendritic cells are associated with increased host susceptibility to Haemophilus ducreyi infection in human volunteers. Journal of Infection and Immunity. 2007, 75, 5686-5697.

41.  Cibull TL, Jones TD, Li L, Eble JN, Baldridge LA, Malott SR, Luo Y, Cheng L. Overexpression of PIM-1 during progression of prostatic adenocarcinoma. Journal of Clinical Pathology 2006, 59: 285-288.

40.  Marraffa JM., Li L., Ong G., and Lehman DF. Profound metoprolol induced bradycardia precipitated by Darvocet. Clinical Pharmacology and Therapeutics, 2006, 79, 282-286.

39.  Schneider B. P., Skaar T., Sledge G. W., Badve S., Li L., and Flockhart D. A. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Research and Treatment 2006, 96, 209-215.

38.  Li L., Hall S., and Desai M. QT Analysis. Encyclopedia of Biopharmaceutical Statistics. 2006. Marcel Dekker.

37.  Sanda C., Weitzel P., Tsukahara T., Schaley J., Edenberg H., Stephen M., McClintick J., Blatt L., Li L., Brodsky L., and Taylor M. Differential gene induction by type I and II interferons and their combination. Journal of Interferon and Cytokine Research 2006, 26, 462-472.

36.  Srirangam A., Mitra R., Wang M., Gorski C., Badve S., Baldridge L.A., Hamilton J., Hawes J., Li L., Orschell C.M., Srour E.F., Blum J.S., Sledge W.G., Nakshatri H., and Potter D.A. Effect of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clinical Cancer Research, 2006, 12, 1883-1896.

35.  Wei S., Balch C., Paik H., Kim Y, Baldwin R., Liyanarachchi S., Li L., Wang Z., Wan J., Davuluri R., Karlan B., Gifford G., Brown R., Kim S., Huang T., and Nephew K. Prognostic DNA methylation biomarkers in ovarian cancer. Clinical Cancer Research 2006, 12, 2788-2794.

34.  Borges-Gonzulas S., Desta Z., Li L., Skaar, T., Ward B., Nguyen A., Jin Y., Storniolo M., Nikoloff M., Koch W., Hayes D., Stearns V., and Flockhart D. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clinical Pharmacology and Therapeutics 2006, 80, 61-74.

33.  Shen, C., Li L., and Chen J. A statistical framework to discover true associations from multi-protein complex pull-down proteomics data sets. Proteins: Structure, Function, and Bioinformatics 2006, 64, 436-443.

32.  Lim Y., Li L., Desta D., Zhao Q., Rae, J., Flockhart D. A., and Skaar T. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. Journal of Pharmacology and Experimental Therapeutics, 2006, 318: 502-513.

31.  Li L., Cheng A. S. L., Jin V., Paik H. H., Fan M., Li X., Zhang W., Robarge J., Balch K., Davuluri R. V., Kim S., Huang T., Nephew K. A Mixture Model Based Discriminate Analysis for Identifying Ordered Transcription Factor Binding Site Pairs in Gene Promoters Directly Regulated by Estrogen Receptor-a. Bioinformatics, 2006, 22: 2210-2216.

30.  Hahn N. M., Marsh S., Fisher W., Langdon R., Zon R., Browning M., Johnson C. S., Scott-Horton T J., Li L., McLeod H L., Sweeney C J. A Hoosier oncology group randomized phase II study of docetaxel plus vinorelbine and docetaxel plus estramustine in combination for the treatment of hormone refractory prostate cancer with pharmacogenetic survival analysis. Clinical Cancer Research, 2006 12, 6094-6099.

29.  Chen Q., Yang Y., Li L., and Zhang J. T. The amino terminus of the human multidrug resistance transporter ABCC1 has a U-shaped folding with a gating function. Journal of Biological Chemistry, 2006, 281, 31152-31163.

28.  Fan M., Yan P. S., Hartman-Frey C., Chen L., Paik H., Abbosh P., Cheng A. S. L, Li L., Huang H. M. T., and Nephew K. Breast cancer cells with acquired resistance to 4-hydroxytamoxifen and fulvestrant display divergent gene expression and DNA methylation signatures. 2006, Cancer Research, 66, 11964-11966.

27.  Jin Y, Desta Z, Stearns V., Ward B., Ho H., Lee J., Skaar T., Storniolo A. M., Li L., Araba A., Blanchard R., Nguyen A., Ullmer L., Hayden J, Lemler S., Weinshilboum R. M., Rae J. M., Hayes D. F., Flockhart D. A. Effects of CYP2D6 Genotype and Antidepressants on Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment. Journal of National Cancer Institute. 2005, 97, 30-39.

26.  Ho H., Pinto A., Hall S. D., Flockhart D. A., Li L., Skaar, T., Cadman, P., O’Connor D. T., Wagner U, Fineberg N., and Weinberger M. H. The Association Between the CYP3A5 Genotype and Blood Pressure. Hypertension. 2005, 45, 294-298.

25.  Li L, Shi H, Yiannoutsos C, Huang Tim and Nephew K. Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system. Journal of Computational Biology. 2005, 12, 370-390.

24.  Adigun A. Q., Pinto A. G., Flockhart D. A., Gorski J. C., Li L., Hall S. D., and Chalasani N. Effect of Cirrhosis and liver transplantation on the gender difference in QT interval. The American Journal of Cardiology, 2005, 95, 691- 694.

23.  Borges S., Li L., Hamman M. A., Jones D. R., Hall S. D., and Gorski C. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metabolism and Disposition, 2005, 33, 1052-1055.

22.  Rae J., Goetz M., Hayes D., Li L. Storniolo A., Stearns V., and Flockhart D. Letter to the Editor. Breast Cancer Research, 2005, 29, 7.

21.  Shen, C., Li L., and Chen J. Discover True Association Rates in Multi-protein Complex Proteomics Data Sets. Proceedings of the IEEE Computational Systems Biology Bioinformatics Conference, Stanford University, Stanford, CA, published by IEEE Computer Society Press, 2005, 1, 167-174.

20.  Li L. Statistical Methods in Bioinformatics – A review. Briefings in Bioinformatics, 2005, 6, 412.

19.  Li L, Huang J, Sun S, Shen J, Unverzagt F, Gao S, Hendrie H, Hall K, and Hui S. Selecting Pre-Screening Items for EARLY INTERVENTION Trials of Dementia – A Case Study. Statistics in Medicine, 2004, 23, 271-283.

18.  Pan C., Kinch, M. S., Sweeney, C. J., Li L., Zhang S., Baldridge L .A., Koch M. O., Ulbright T. M., Eble J. N., Cheng K. PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) Expression Correlates with Progression of Prostate Cancer. Clinical Cancer Research, 2004, 10, 1333-1337.

17.  Cheng L, Pan C, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, Ulbright TM, Eble JN. Loss of 14-3-3s in Prostate Cancer and Its Precursors. Clinical Cancer Research, 2004, 10, 3064-3068.

16.  Li L, Lin X, Brown M, Gupta S. and Lee K. A population pharmacokinetic model with time-dependent covariates measured with errors. Biometrics, 2004, 60, 451-460.

15.  Li L, Desai M., Desta Z., and Flockhart D. QT analysis: a complex answer to a ‘simple’ problem. Statistics in Medicine, 2004, 23, 2625-2643.

14.  Arora R., Koch M. O., Eble J. N., Ulbright T. M., Li L. and Chen L. Heterogeneity of Gleason Grade in Multifocal Adenocarcinoma of the Prostate. Cancer 2004, 100, 2362-6.

13.  Hong H., Kao C., Jeng M. H., Eble J. N., Koch M. O., Gardner T. A., Zhang S., Li L., Pan C., Hu Z., MacLennan G. T., Cheng L. Aberrant Expression of CARM1, a Transcriptional Coactivator of Androgen Receptor, in the Development of Prostate Cancer and Androgen-Independent Status. Cancer, 2004, 101, 83-89.

12.  Sweeney C., Li L., Shanmugam R., Bhat-Nakshatri P., Jayaprakasan V., Baldridge L. A., Gardner T., Smith M., Nakshatri H., Cheng L. Nuclear Factor Kappa B is Constitutively Activated in Prostate Cancer In Vitro and is Over-expressed in Prostatic Intra-epithelial Neoplasia and Adenocarcinoma of the Prostate. Clinical Cancer Research, 2004, 10, 5501-5507.

11.  Chen J., Sivachenkoand A. and Li L. High-throughput Protein Interactome Data: Minable or Not?, Proceedings of the 4th ACM SIGKDD Workshop on Data Mining in Bioinformatics at the International Conference on Knowledge Discovery and Data Mining, Seattle, WA, 2004, p18-23.

10.  Desai M, Li L, Desta Z, Malik M, and Flockhart D. Variability of Heart Rate Correction Methods for the QT Interval: Potential for QTc Overestimation with a Low Dose of Haloperidol. 2002. British Journal of Clinical Pharmacology, 2003, 55, 511-517.

9.  Desai M., Tanus-Santos J., Li L., Gorski J. C., Arefayene M., Liu Y., Desta Z., and Flockhart D. Pharmacokinetics and QT interval pharmacodynamics of oral halporeridol in poor and extensive metabolizers of CYP2D6. The Pharmacogenomic Journal, 2003, 3, 105-113.

8.  Zeng G, Hu, Z, Kinch MS, Pan C, Flockhart, Kao C,Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L. High level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. American Journal of Pathology, 2003, 163, 2271-6.

7.  Song J, Tata D, Li L, Taylor J, Bao S, and Miller DL. Combined shockwave and immuno-gene therapy of mouse melanoma and renal carcinoma tumors. Ultrasound in Medicine and Biology, 2002, 28, 957-964.

6.  Li L, Brown M, Lee K. and Gupta S. Estimation and inference for a spline-enhanced nonlinear population pharmacokinetic model. Biometrics, 2002; 58, 601-611.

5.  Wang Z, Hall S D, Maya JF, Li L, Ashgar A, and Gorski CJ. Diabetes mellitus increases the in vivo activity of cytochrome P450 2e1 in human. British Journal of Clinical Pharmacology, 2002, 55, 77-85.

4.  McKeever P. E., Junck L., Strawderman M., and Blaivas M, Tkaczyk A, Cates MA, Yan M and Li L. Proliferation Index is related to patient age in Glioblastoma. Neurology 2001, 56, 1216-1218.

3.  Chaib H., Rubin M.A., Mucci N.R., Li L., Taylor M.J., Day M.L., Rhim J., and Macoska J. Activated in Prostate Cancer: A PDZ Domain-Containing Protein Highly Expressed in Human Primary Prostate Tumors. Cancer Research 2001, 61, 2390-2394.

2.  Vladmir K and Li L. A new symmetry test for multivariate distribution. Journal of Multivariate Analysis 1998, 65, 228-44.

1.  Smith D.C., Redman B.G., Flaherty L.E., Li L., Strawderman M., and Pienta K.J. A phase II trial of oral diethylstilbesterol as a second line hormonal agent in advanced prostate cancer. Urology 1998, 52, 257-260.